MGO One Seven LLC Reduces Position in Novo Nordisk A/S $NVO

MGO One Seven LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 64.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,999 shares of the company’s stock after selling 16,037 shares during the quarter. MGO One Seven LLC’s holdings in Novo Nordisk A/S were worth $458,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth about $25,000. WealthCollab LLC raised its position in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: New clinical data for oral Wegovy and higher-dose Wegovy showed strong weight-loss results, improved mobility, and broader benefits, reinforcing Novo Nordisk’s obesity-growth story and helping offset worries about slowing momentum. Novo Nordisk (NVO) Announces Positive Early Response Data from Oral Wegovy (25 mg) Trial
• Positive Sentiment: The company’s latest Q1 results beat expectations and it raised its 2026 outlook, which supports the case that newer product launches are still driving sales growth. Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly’s Growing Pressure?
• Positive Sentiment: Investor-friendly commentary and bullish takes continue to highlight Novo Nordisk as undervalued relative to its long-term growth potential, especially if new indications expand its blockbuster franchise. Best Healthcare Stocks to Buy in 2026
• Neutral Sentiment: Several market commentaries and analyst forecast pages were published on NVO, but they appear to be mostly rating/price-target updates rather than new company-specific catalysts. Novo Nordisk A/S (NVO) stock forecast and price target
• Neutral Sentiment: Novo Nordisk also disclosed gifted share transactions linked to CFO associates, which is worth noting but does not by itself appear to change the company’s fundamentals. Novo Nordisk Discloses Gifted Share Transactions Linked to CFO Associates
• Negative Sentiment: Bearish commentary argues Novo Nordisk’s valuation may still be a value trap, and competition from Eli Lilly’s expanding GLP-1 pipeline remains a real threat to obesity-market share. Novo Nordisk: Why I Won’t Upgrade

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $45.82 on Friday. The company’s 50 day simple moving average is $39.61 and its 200-day simple moving average is $46.71. The firm has a market cap of $204.60 billion, a PE ratio of 10.76, a price-to-earnings-growth ratio of 4.19 and a beta of 0.77. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.47 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on NVO shares. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.